US 11,987,843 B2
Bisulfite-free, base-resolution identification of cytosine modifications
Chunxiao Song, Oxford (GB); and Yibin Liu, Oxford (GB)
Assigned to Ludwig Institute for Cancer Research, LTD, Zurich (CH)
Filed by Ludwig Institute for Cancer Research Ltd, Zurich (CH)
Filed on Mar. 7, 2022, as Appl. No. 17/688,427.
Application 17/688,427 is a continuation of application No. 17/201,825, filed on Mar. 15, 2021, granted, now 11,306,355.
Application 17/201,825 is a continuation of application No. 16/960,510, previously published as PCT/US2019/012627, filed on Jan. 8, 2019.
Claims priority of provisional application 62/771,409, filed on Nov. 26, 2018.
Claims priority of provisional application 62/660,523, filed on Apr. 20, 2018.
Claims priority of provisional application 62/614,798, filed on Jan. 8, 2018.
Prior Publication US 2022/0282323 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12P 17/16 (2006.01); C12Q 1/6844 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/6874 (2018.01); C12Q 1/6876 (2018.01)
CPC C12Q 1/6869 (2013.01) [C12P 17/16 (2013.01); C12Q 1/6844 (2013.01); C12Q 1/6874 (2013.01); C12Q 1/6876 (2013.01); C12Q 2600/154 (2013.01); C12Y 204/01026 (2013.01); C12Y 204/01027 (2013.01)] 18 Claims
 
1. A method for converting a modified cytosine to dihydrouracil (DHU) comprising:
i) contacting a nucleic acid sample comprising a modified cytosine with an oxidizing agent to produce 5-carboxylcytosine (5caC) and/or 5-formylcytosine (5fC); and
ii) contacting the nucleic acid sample comprising 5caC and/or 5fC with a borane reducing agent.